Learning 2 Sleep L2S Valuation

Is L2S undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of L2S when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate L2S's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate L2S's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for L2S?

Key metric: As L2S is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for L2S. This is calculated by dividing L2S's market cap by their current revenue.
What is L2S's PS Ratio?
PS Ratio	3.7x
Sales	SEK 2.88m
Market Cap	SEK 10.56m

L2S key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.6x
Enterprise Value/EBITDA	-1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does L2S's PS Ratio compare to its peers?

The above table shows the PS ratio for L2S vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.6x
NGS NGS Group	0.2x	n/a	SEK 77.4m
HEGR Hedera Group	0.06x	n/a	SEK 36.1m
DEDI Dedicare	0.3x	n/a	SEK 592.9m
ALTE Alteco Medical	5.8x	n/a	SEK 17.2m
L2S Learning 2 Sleep L2S	3.7x	n/a	SEK 10.6m

Price-To-Sales vs Peers: L2S is expensive based on its Price-To-Sales Ratio (3.7x) compared to the peer average (2.5x).

Price to Sales Ratio vs Industry

How does L2S's PS Ratio compare vs other companies in the European Healthcare Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap

7 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: L2S is expensive based on its Price-To-Sales Ratio (3.7x) compared to the European Healthcare industry average (0.7x).

Price to Sales Ratio vs Fair Ratio

What is L2S's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

L2S PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate L2S's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Mentice

SEK 560.0m

Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas.

MNTC

SEK 21.90

2.8%

-46.6%

Iconovo

SEK 80.5m

Develops and licenses inhalation medications in Sweden.

ICO

SEK 5.06

2.4%

-45.1%

Dignitana

SEK 95.8m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.19

3.5%

-45.9%